Termination of the Sales Agreement with Becton, Dickinson and Company, Japan for Blood Culture Testing Products
First written in FY2020-Q1. 1 of 3 entries say "Restated". Latest entry: FY2020.
The whole theme swung hardest in 2018: 7 of 41 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- FY2020AdvancedAnnual report
「Sales of microbiology testing reagents declined to ¥4,623 million, down 10.3% year on year, due in part to the termination of the sales agreement for blood culture testing products previously sourced from Becton, Dickinson and Company Japan.」
The impact of the termination of the sales agreement was confirmed in full-year microbiology testing reagent sales of ¥4,623 million, down 10.3% year on year. - FY2020-Q2RestatedAnnual report
「Sales of microbiology testing reagents declined to ¥2,311 million, down 8.6% year on year, due in part to the termination of the sales agreement for blood culture testing products previously sourced from Becton, Dickinson and Company Japan.」
Continued to disclose the impact of the termination of the blood culture testing product sales agreement on microbiology testing reagents and the resulting decline in sales. - FY2020-Q1First statedAnnual report
「Sales of microbiology testing reagents declined to ¥1,124 million, down 9.8% year on year, due in part to the termination of the sales agreement for blood culture testing products previously sourced from Becton, Dickinson and Company Japan.」
The termination of the sales agreement for blood culture testing products previously sourced from Becton, Dickinson and Company Japan, and the resulting decline in sales of microbiology testing reagents, were first disclosed.